FOLH1 and prostate carcinoma: Agents like Gallium-68 (68Ga)-PSMA-11 and 18F-DCFPyL have been approved by the FDA for staging unfavorable prostate cancer patients [7] and evaluating sites of recurrence following a rising prostate-specific antigen (PSA) after curative treatment [8].